Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience v stents: Insights from the gender-stratified, randomized, controlled TWENTE trial

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 3, 2013, Pages 396-405

  Tandjung, Kenneth ^a   Basalus, Mounir W Z ^a   Sen, Hanim ^a   Stoel, Martin G ^a   Van Houwelingen, K Gert ^a   Louwerenburg, J Hans W ^a   De Man, Frits H A F ^a   Linssen, Gerard C M ^b   Saïd, Salah A M ^b   Kleijne, Miep A W J ^c   Van Der Palen, Job ^a,d   Von Birgelen, Clemens ^a,d  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

^c Streekziekenhuis Koningin Beatrix ^*  (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

drug eluting stent(s); gender; percutaneous coronary intervention; Resolute; women; Xience V

Indexed keywords

EVEROLIMUS; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE PERIOD; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STENT THROMBOSIS; TREATMENT FAILURE;

DRUG-ELUTING STENT(S); GENDER; PERCUTANEOUS CORONARY INTERVENTION; RESOLUTE; WOMEN; XIENCE V;

AGE FACTORS; AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SEX FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883219140     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24848     Document Type: Article

References (34)

1. Maas AH, van der Schouw YT, Regitz-Zagrosek V, Swahn E, Appelman YE, Pasterkamp G, Ten CH, Nilsson PM, Huisman MV, Stam HC, Eizema K, Stramba-Badiale M,. Red alert for women's heart: The urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J 2011; 32: 1362-1368.
2. Chieffo A, Hoye A, Mauri F, Mikhail GW, Ammerer M, Grines C, Grinfeld L, Madan M, Presbitero P, Skelding KA, Weiner BH, Mehran R,. Gender-based issues in interventional cardiology: A consensus statement from the Women in Innovations (WIN) initiative. EuroIntervention 2010; 5: 773-779.
3. Mehran R, Kini AS,. Sex-related outcomes after drug-eluting stent: should we never mind or mind the gap?. JACC Cardiovasc Interv 2010; 3: 1260-1261.
4. Anonymous WomenHeart and the Society for Women's Health Research. 2011 10Q Report: Advancing Women's Heart Health Through Improved Research, Diagnosis, and Treatment 2011.
5. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB, Newby LK,. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010; 3: 135-142.
6. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, Mehran R, Leon MB, Russell ME, Ellis SG, Stone GW,. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 2005; 45: 1180-1185.
7. Onuma Y, Kukreja N, Daemen J, Garcia-Garcia HM, Gonzalo N, Cheng JM, van Twisk PH, van DR, Serruys PW,. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: Insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. JACC Cardiovasc Interv 2009; 2: 603-610.
8. Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, Mehran R,. Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol 2007; 50: 2111-2116.
9. Kedhi E, Joesoef KS, McFadden E, Wassing J, van MC, Goedhart, D, Smits PC,. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375: 201-209.
10. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van LF, Windecker S,. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136-146.
11. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ,. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
12. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Said SA, Kleijne MA, Sen H, Lowik MM, van der Palen J, Verhorst PM, de Man FH,. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting xience V stents in real-world patients: The TWENTE Trial. J Am Coll Cardiol 2012; 59: 1350-1361.
13. Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW,. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: Clinical and angiographic results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv 2009; 74: 719-727.
14. Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, Stone GW,. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol 2011; 107: 841-848.
15. Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, de Man FH, Louwerenburg JW, Said SA, Linssen GC, Kleijne MA, van der PJ, Huisman J, Verhorst PM, von Birgelen C,. TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: Study design, rationale and objectives. Neth Heart J 2010; 18: 360-364.
16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
17. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW,. Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention 2010; 5: 871-874.
18. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di MC, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P,. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008; 372: 1163-1173.
19. Vaartjes I, van Dis I, Visseren FLJ, Bots ML,. Cardiac and vascular diseases in the Netherlands 2011, data on lifestyle and risk factors, prevalence of disease, and mortality. In: Part 1: Cardiac surgery, percutaneous coronary interventions, interventions for cardiac rhythm disturbances and heart transplantations. The Hague, the Netherlands: Dutch Heart Foundation 2012: 23-32.
20. Vranckx P, Boersma E, Garg S, Valgimigli M, van Es GA, Goedhart D, Serruys PW,. Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: Insights from 33 prospective stent trials in Europe. EuroIntervention 2011; 7: 859-871.
21. Brown RA, Williams M, Barker CM, Mauri L, Meredith IT, Fajadet J, Wijns W, Leon MB, Kandzari DE,. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: Comparison of angiographic and late-term clinical results. Catheter Cardiovasc Interv 2010; 76: 804-813.
22. Nakatani D, Ako J, Tremmel JA, Waseda K, Otake H, Koo BK, Miyazawa A, Hongo Y, Hur SH, Sakurai R, Yock PG, Honda Y, Fitzgerald PJ,. Sex differences in neointimal hyperplasia following endeavor zotarolimus-eluting stent implantation. Am J Cardiol 2011; 108: 912-917.
23. Mikhail GW, Gerber RT, Cox DA, Ellis SG, Lasala JM, Ormiston JA, Stone GW, Turco MA, Joshi AA, Baim DS, Colombo A,. Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: Results of the TAXUS Woman analysis. JACC Cardiovasc Interv 2010; 3: 1250-1259.
24. Mehta RH, Leon MB, Sketch MH, Jr,. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: An analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. Am J Cardiol 2007; 100: 62M-70M.
25. Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW,. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: Two-year analysis. EuroIntervention 2010; 5: 788-794.
26. Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre KM,. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993; 87: 720-727.
27. Malenka DJ, O'Connor GT, Quinton H, Wennberg D, Robb JF, Shubrooks S, Kellett MA, Jr, Hearne MJ, Bradley WA, VerLee P,. Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13,061 procedures. Northern New England Cardiovascular Disease Study Group. Circulation 1996; 94: II99-II104.
28. Watanabe CT, Maynard C, Ritchie JL,. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol 2001; 88: 848-852.
29. Berger JS, Sanborn TA, Sherman W, Brown DL,. Influence of sex on in-hospital outcomes and long-term survival after contemporary percutaneous coronary intervention. Am Heart J 2006; 151: 1026-1031.
30. Kovacic JC, Mehran R, Karajgikar R, Baber U, Suleman J, Kim MC, Krishnan P, Dangas G, Sharma SK, Kini A,. Female gender and mortality after percutaneous coronary intervention: Results from a large registry. Catheter Cardiovasc Interv 2011; 80: 514-521.
31. Hodgson JM, Stone GW, Lincoff AM, Klein L, Walpole H, Bottner R, Weiner BH, Leon MB, Feldman T, Babb J, Dehmer GJ,. Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv 2007; 69: 327-333.
32. Abbott JD, Vlachos HA, Selzer F, Sharaf BL, Holper E, Glaser R, Jacobs AK, Williams DO,. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007; 99: 626-631.
33. Hoffmann R, Klinker H, Adamu U, Kelm M, Blindt R,. The risk of definitive stent thrombosis is increased after off-label stent implantation irrespective of drug-eluting stent or bare-metal stent use. Clin Res Cardiol 2009; 98: 549-554.
34. Jensen LO, Tilsted HH, Thayssen P, Kaltoft A, Maeng M, Lassen JF, Hansen KN, Madsen M, Ravkilde J, Johnsen SP, Sorensen HT, Thuesen L,. Paclitaxel and sirolimus eluting stents versus bare metal stents: Long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010; 5: 898-905.